- Home
- WLKP vs RCUS Comparison
WLKP vs RCUS Comparison
Compare WLKP & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- RCUS
- Stock Information
- Founded
- WLKP 2014
- RCUS 2015
- Country
- WLKP United States
- RCUS United States
- Employees
- WLKP N/A
- RCUS N/A
- Industry
- WLKP Major Chemicals
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- WLKP Industrials
- RCUS Health Care
- Exchange
- WLKP Nasdaq
- RCUS Nasdaq
- Market Cap
- WLKP 833.7M
- RCUS 906.4M
- IPO Year
- WLKP 2014
- RCUS 2018
- Fundamental
- Price
- WLKP $22.37
- RCUS $8.59
- Analyst Decision
- WLKP
- RCUS Buy
- Analyst Count
- WLKP 0
- RCUS 10
- Target Price
- WLKP N/A
- RCUS $23.75
- AVG Volume (30 Days)
- WLKP 34.1K
- RCUS 1.1M
- Earning Date
- WLKP 08-05-2025
- RCUS 08-07-2025
- Dividend Yield
- WLKP 8.48%
- RCUS N/A
- EPS Growth
- WLKP N/A
- RCUS N/A
- EPS
- WLKP 1.49
- RCUS N/A
- Revenue
- WLKP $1,088,852,000.00
- RCUS $141,000,000.00
- Revenue This Year
- WLKP $8.90
- RCUS N/A
- Revenue Next Year
- WLKP $6.87
- RCUS $28.73
- P/E Ratio
- WLKP $14.93
- RCUS N/A
- Revenue Growth
- WLKP N/A
- RCUS N/A
- 52 Week Low
- WLKP $21.19
- RCUS $6.50
- 52 Week High
- WLKP $25.04
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- WLKP 53.50
- RCUS 47.18
- Support Level
- WLKP $21.96
- RCUS $7.92
- Resistance Level
- WLKP $22.48
- RCUS $8.87
- Average True Range (ATR)
- WLKP 0.30
- RCUS 0.47
- MACD
- WLKP 0.06
- RCUS -0.09
- Stochastic Oscillator
- WLKP 83.97
- RCUS 43.17
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.